Articles Related to CD4
Development of SARS-Cov-2 Circulating Immune Complex Candidate, (CRCx) as A New Promising Vaccine Eliciting Broad Immune Response.
There is a need to develop a universal vaccine that can boost immunity to coronaviruses if some modifications in their structure occur. This is what we are dealing with nowadays: a virus that can mutate its structure, while immunity is standing still in facing the virus. We report on preclinical trials of CRCx 3 and CRCx 2 vaccine candidates in inducing an elevated level of positive neutralizing antibodies as well as a cellular immune response in an animal model to provide protection against SARS-CoV-2. Highly efficient protection against SARS-CoV-2 was obtained with three-dose immunization using 0.25 ml of CRCx vaccine with a 25-mm needle at 7-day intervals between successive injections. In addition, CRCx vaccine candidates exhibit efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of CRCx in a clinical trial.
Acquired Immune Deficiency Syndrome (AIDS) is a spectrum of conditions caused by infection with the human immunodeficiency virus (HIV). They get it after being infected with the HIV virus. HIV (human immunodeficiency virus) is a retrovirus that primarily infects components of the immune system.
This is a cross-sectional multicenter study to determine the prevalence of HIV sero- discordancy and the associated factors. A total of 166 respondents had questionnaire-based interview. All the respondents were PLHIV and most(87%) have been in heterosexual relationship for at least one year.
Accelerated aging and higher co-morbidity prevalence have increased non-antiretroviral (ARV) medications for HIV patients. We examined, over a 12 month period, non-ARV medication burden among HIV-positive patients 18-49 and ≥50 years using a comprehensive U.S. healthcare claims database in an age-and-gender matched analysis (1:3 matching ratio of cases to controls). Primary outcomes of interest included the median and mean number of unique non-ARV drug substances during the one month period with the highest number of prescriptions filled for each individual, and the mean number of unique classes of medication.